hrp0098p1-59 | GH and IGFs 1 | ESPE2024

Near adult height in prepubertal children treated with growth hormone: differences between definite growth hormone deficiency (dGHD), short stature unresponsive to stimulation tests (SUS) and idiopathic short stature (ISS)

Tamaro Gianluca , Andrea Lanzetta Maria , Ove Carlsson Martin , La Torre Daria , Stefano Tresoldi Alberto , Bruschini Pietro , Tornese Gianluca

Objective: To understand whether characterization into definite growth hormone deficiency (dGHD; peak GH <8 ug/L and identifiable genetic, functional or anatomical cause), short stature unresponsive to stimulation test (SUS; peak GH <8 ug/L but without any identifiable cause) or idiopathic short stature (ISS; peak GH ≥8) can predict the near adult height (NAH) of prepubertal children treated with recombinant human growth hormone (rhGH).<p class="a...

hrp0092p1-89 | Growth and Syndromes (to include Turner Syndrome) | ESPE2019

Clinical Outcomes in Primary Empty Sella (ES) Syndrome in Childhood-Onset Growth Hormone Deficiency: Data from KIGS (Pfizer International Growth Database)

Maghnie Mohamad , Carlsson Martin , Aydin Ferah , Camacho-Hübner Cecilia

Background: The incidence of ES in children varies greatly depending on the population surveyed, ranging from 1.2%-9% to 68% (children without and with known endocrinopathies, respectively). MRI is the main diagnostic tool for screening pituitary and in a previous KIGS study, 3.0% of patients with GHD were identified with ES and 7.8% with pituitary hypoplasia (Maghnie et al, EJE (2013).Aim: T...

hrp0092p1-379 | Growth and Syndromes (to include Turner Syndrome) (2) | ESPE2019

Adult Height Prediction by Bone Age Determination in Children with Idiopathic Growth Hormone Deficiency (IGHD): Analysis of KIGS Data

Reinehr Thomas , Carlsson Martin , Chrysis Dionisios , Camacho-Hübner Cecilia

Background: The precision of adult height prediction by bone age determination in children with idiopathic growth hormone deficiency (IGHD) is unknown.Patients and Methods: The near adult height (NAH) of patients with IGHD with prepubertal onset of growth hormone treatment (GH) in the KIGS database was compared to adult height prediction based on bone ages (BA) >7 years using the Bailey Pinneau (BP) or Tanner-Whiteho...

hrp0097p1-110 | Growth and Syndromes | ESPE2023

Comparison of long-term height outcomes in pediatric patients with growth hormone deficiency receiving once weekly somatrogon with those of matched patients treated with once-daily somatropin in the Kabi/Pfizer International Growth Study (KIGS)

Paliwal Yuvika , Carlsson Martin , Zhang Richard , Lee Peter , Korth-Bradley Joan , Taylor Carrie , Cara Jose

Objectives: Somatrogon is a long-acting recombinant human growth hormone (GH) approved in the EU and other countries for once-weekly treatment of pediatric patients with GH deficiency (GHD). In this analysis, height outcomes of somatrogon-treated patients in a phase 3 trial (CP-4-006) were compared with historical data from matched somatropin-treated patients enrolled in KIGS.Methods: In trial CP-4-006, patients were ran...

hrp0098p2-156 | GH and IGFs | ESPE2024

Dosage of recombinant human growth hormone across geographic regions at enrolment into the Kabi/Pfizer International Growth Study (KIGS)

Geffner Mitchell , Thomas Marc , Cutfield Wayne , Gomez Roy , Tanaka Toshiaki , Carlsson Martin , Wajnrajch Michael

Objectives: The Kabi/Pfizer International Growth Study (KIGS) was the largest and longest running international database of pediatric patients receiving recombinant human growth hormone (rhGH). The objective of the current analysis is to describe the dosage of rhGH at enrolment into KIGS according to diagnosis and geographical region.Methods: Between 1987-2012, 83,803 pediatric patients were enrolled into KIGS if they re...

hrp0094p1-135 | Growth Hormone and IGFs A | ESPE2021

Long-term safety of growth hormone in adults and adolescents with growth hormone deficiency: An overview of the full-cohort in KIMS

Johannsson Gudmundur , Touraine Philippe , Feldt-Rasmussen Ulla , Pico Antonio , Vila Greisa , Carlsson Martin , Beek Andre P van , Wajnrajch Michael P , Gomez Roy , Yuen Kevin CY ,

Objective: KIMS (Pfizer International Metabolic Survey) was a postmarketing surveillance study of growth hormone (GH) replacement in adults and adolescents with GH deficiency (GHD) that concluded in October 2012. This analysis aimed to evaluate the overall safety outcomes from the full cohort of GH-treated patients of KIMS.Methods: Data were collected on adults and adolescents with confirmed GHD and closed epiphyses trea...

hrp0094p1-138 | Growth Hormone and IGFs A | ESPE2021

Safety and effectiveness of pediatric growth hormone therapy: Results from the full cohort in KIGS

Maghnie Mohamad , Ranke Michael B , Geffner Mitchell E , Vlachopapadopoulou Elpis , Dorr Helmuth G , Wikland Kerstin Albertsson , Ibanez Lourdes , Carlsson Martin , Cutfield Wayne , Rooman Raoul , Gomez Roy , Wajnrajch Michael P , Linglart Agnes , Stawerska Renata , Polak Michel , Grimberg Adda ,

Objective: KIGS (Pfizer International Growth Survey) was a large, international database of pediatric patients who received recombinant human growth hormone (rhGH) as prescribed in real-world clinical settings. This analysis evaluated the long-term safety and efficacy data from all participants until KIGS close in 2012.Methods: Children with growth disorders and treated with rhGH (Genotropin® [somatropin]...

hrp0097p1-324 | Growth and Syndromes | ESPE2023

PROGRES, a multi-country, non-interventional, prospective study of patients receiving human growth hormone treatment under routine clinical care: Study update

Geffner Mitchell , Maniatis Aristides , Ibañez Lourdes , La Torre Daria , Huang Carol , Darendeliler Feyza , Dattani Mehul , Maghnie Mohamad , Phillip Moshe , Horikawa Reiko , Gomez Roy , Viswanathan Shilpa , Carlsson Martin , Wajnrajch Michael

Objectives: Children with growth hormone deficiency (GHD) are usually treated with once-daily injections of recombinant human growth hormone (rhGH). Somatrogon is a long-acting rhGH (LAGH) approved in the EU and other countries for once-weekly treatment of children with short stature. The Pfizer Registry of Outcomes in Growth hormone RESearch (PROGRES) study will assess the long-term safety and effectiveness of once-weekly somatrogon and once-daily rhGH prepar...

hrp0084p2-465 | Growth | ESPE2015

Making Adult Height Prediction Complete: Forecasting the Age of the Growth Spurt and the Height and Velocity Trajectories Until Adulthood

Martin David , Mortensen Sofus , Jenni Oscar , Thodberg Hans Henrik

Background: Adult height prediction (AHP) based on bone age appears as an incomplete procedure – it does not reveal the path from the present to the end-point. Growth charts offer little help in this respect because they average over children with different age of growth spurt (AGS).Objective and hypotheses: To extend AHP by also forecasting AGS and the entire height and velocity trajectories until adulthood and displaying this in a growth chart mad...

hrp0097fc14.4 | Late Breaking | ESPE2023

Improvement in insulin sensitivity and glucose metabolism in adolescents with obesity treated with once-weekly semaglutide 2.4 mg: a secondary analysis of the STEP TEENS trial

Arslanian Silva , Goldman Bryan , Gies Inge , M. Harder-Lauridsen Nina , Karlsson Tobias , Kelly Aaron , Wabitsch Martin , Weghuber Daniel

Obesity in adolescents is associated with increased risk of prediabetes and type 2 diabetes (T2D) and long-term complications in adulthood. Data regarding the effects of anti-obesity medications on glycaemic outcomes in adolescents are sparse. STEP TEENS (NCT04102189), a phase 3a, double-blind, placebo-controlled randomised trial in adolescents 12 to <18 years of age with obesity demonstrated that once-weekly subcutaneous semaglutide 2.4 mg provided a greater percentage red...